MGC Pharmaceuticals Ltd (ASX, LSE: MXC, ‘MGC Pharma’ or ‘the Company’), a European based bio-pharma company specialising in the production and development of phytomedicines, has had a peer reviewed paper into the Effect of ArtemiC in patients with COVID-19 published in the Journal of Cellular and Molecular Medicine.
Key Highlights:
- Journal of Cellular and Molecular Medicine have published a study into the effect of MGC Pharma’s proprietary product ArtemiC™ in patients with Covid-19.
- The Phase II prospective study is peer reviewed and is available for all to read
- This is the first clinical study addressing the safety and tolerability of ArtemiC oral spray and its efficacy in improving symptoms in hospitalized COVID-19 patients.
- These findings suggest that ArtemiC curbed deterioration, possibly by limiting the cytokine storm of COVID-19.
The Phase II prospective study of 50 patients all with COVID-19 concludes that “ArtemiC curbed deterioration, possibly by limiting the cytokine storm of COVID-19, and bears great promise for COVID-19 patients, particularly in those with comorbidities.”
This is the first clinical study addressing the safety and tolerability of ArtemiC™ oral spray and its efficacy in improving symptoms in hospitalized COVID-19 patients and the first scientific article published on ArtemiC™.
The article is open access, and can be read in the Journal of Cellular and Molecular Medicine at the link below: https://onlinelibrary.wiley.com/doi/10.1111/jcmm.17337
